Cited by 1,309Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Open access

Garon, Edward B, Ciuleanu, Tudor-Eliade, Arrieta, Oscar, Prabhash, Kumar, Syrigos, Konstantinos N, Goksel, Tuncay, Park, Keunchil, Gorbunova, Vera, Kowalyszyn, Ruben Dario, Pikiel, Joanna, Czyzewicz, Grzegorz, Orlov, Sergey V, Lewanski, Conrad R, Thomas, Michael, Bidoli, Paolo, Dakhil, Shaker, Gans, Steven, Kim, Joo-Hang, Grigorescu, Alexandru, Karaseva, Nina, Reck, Martin, Cappuzzo, Federico, Alexandris, Ekaterine, Sashegyi, Andreas, Yurasov, Sergey, Pérol, Maurice·2014·The Lancet

DOI 10.1016/s0140-6736(14)60845-x

Open this paper in CoChat — free account

Abstract

Background Ramucirumab is a human IgG1 monoclonal antibody that targets the extracellular domain of VEGFR-2. We aimed to assess efficacy and safety of treatment with docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC) after platinum-based therapy.Methods In this multicentre, double-blind, randomised phase 3 trial (REVEL), we enrolled patients with squamous or non-squamous NSCLC who had progressed during or after a first-line platinum-based chemotherapy regimen. Patients were randomly allocated (1:1) with a centralised, interactive voice-response system (stratified by sex, region, performance status, and previous maintenance therapy [yes vs no]) to receive docetaxel 75 mg/m(2) and either ramucirumab (10 mg/kg) or placebo on day 1 of a 21 day cycle until disease progression, unacceptable toxicity, withdrawal, or death. The primary endpoint was overall survival in all patients allocated to treatment. We assessed adverse events according to treatment received. This study is registered with ClinicalTrials.gov, number NCT01168973.Findings Between Dec 3, 2010, and Jan 24, 2013, we screened 1825 patients, of whom 1253 patients were randomly allocated to treatment. Median overall survival was 10·5 months (IQR 5·1-21·2) for 628 patients allocated ramucirumab plus docetaxel and 9·1 months (4·2-18·0) for 625 patients who received placebo plus docetaxel (hazard ratio 0·86, 95% CI 0·75-0·98; p=0·023). Median progression-free survival was 4·5 months (IQR 2·3-8·3) for the ramucirumab group compared with 3·0 months (1·4-6·9) for the control group (0·76, 0·68-0·86; p<0·0001). We noted treatment-emergent adverse events in 613 (98%) of 627 patients in the ramucirumab safety population and 594 (95%) of 618 patients in the control safety population. The most common grade 3 or worse adverse events were neutropenia (306 patients [49%] in the ramucirumab group vs 246 [40%] in the control group), febrile neutropenia (100 [16%] vs 62 [10%]), fatigue (88 [14%] vs 65 [10%]), leucopenia (86 [14%] vs 77 [12%]), and hypertension (35 [6%] vs 13 [2%]). The numbers of deaths from adverse events (31 [5%] vs 35 [6%]) and grade 3 or worse pulmonary haemorrhage (eight [1%] vs eight [1%]) did not differ between groups. Toxicities were manageable with appropriate dose reductions and supportive care.Interpretation Ramucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC.Funding Eli Lilly.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(14)60845-x

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Cancer statistics, 2012
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citation
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
Shepherd, F. A., Dancey, J. E., Ramlau, R., Mattson, K. V., Gralla, R. J., O’Rourke, M. A., Levitan, N. I., Gressot, L., Vincent, M. D., Burkes, R. L., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,178
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
Fuchs, C., Tomášek, J., Cho, J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. D., Aprile, G., Ferry, D., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,031
Self-citation
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,948

Show all 35 references

Research works printed but not linked: 1

Wilke, 2014, J Clin Oncol, 32

Sorted by citations

Items 201–300 of 1,001

A Phase II Clinical Trial of Apatinib in Pretreated Advanced Non-squamous Non–small-cell Lung Cancer
Wu, F., Zhang, S., Xiong, A., Gao, G., Li, W., Cai, W., Su, C., Chen, X., Zhou, F., Zhao, J., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.06.002 · Cited by 59
Chemotherapy for Advanced-Stage Non–Small Cell Lung Cancer
Du, L., & Morgensztern, D. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000141 · Cited by 58
A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer
Garon, E. B., Neidhart, J. D., Gabrail, N. Y., de Oliveira, M. R., Balkissoon, J., & Kabbinavar, F. F. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s109186 · Cited by 58
Self-citation
Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations
Lam, V. K. L., Tran, H. T., Banks, K. C., Lanman, R. B., Rinsurongkawong, W., Peled, N., Lewis, J., Lee, J. J., Roth, J. A., Roarty, E. B., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.08.020 · Cited by 58
The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer
Low, J. L., Walsh, R. J., Ang, Y. L. E., Chan, G. H. J., & Soo, R. A. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919870360 · Cited by 59
Targeting obesity-related dysfunction in hormonally driven cancers
Rubinstein, M. M. Z., Brown, K. A., & Iyengar, N. M. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01393-y · Cited by 61
Antioxidants stimulate BACH1-dependent tumor angiogenesis
Wang, T., Dong, Y., Huang, Z., Zhang, G., Zhao, Y. H., Yao, H., Hu, J., Tüksammel, E., Cai, H., Liang, N., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci169671 · Cited by 58
The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy
Visconti, R., Morra, F., Guggino, G., & Celetti, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071374 · Cited by 62
Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC
Herbst, R. S., Arkenau, H., Bendell, J. C., Arrowsmith, E. R., Wermke, M., Soriano, A., Penel, N., Santana-Dávila, R., Bischoff, H. G., Chau, I., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.10.004 · Cited by 57
Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients
Garde, J., Martín-Martorell, P., Julián, M. D., Altozano, J. P., Coloma, C. S., García-Sánchez, J., Insa, A., Martín, M., Mielgo-Rubio, X., Marín-Liébana, S., et al. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1829-5 · Cited by 56
New Target Therapies in Advanced Non-Small Cell Lung Cancer: A Review of the Literature and Future Perspectives
de Mello, R. A., Neves, N. M., Tadokoro, H., Amaral, G. A., Castelo‐Branco, P., & Zia, V. A. D. A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113543 · Cited by 59
LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non–Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab
Bonanno, L., De Paoli, A., Zulato, E., Esposito, G., Calabrese, F., Favaretto, A., Santo, A., Conte, A. D., Chilosi, M., Oniga, F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2410 · Cited by 53
Trial watch: Tumor-targeting monoclonal antibodies for oncological indications
Vacchelli, E., Pol, J. G., Bloy, N., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Galon, J., Marabelle, A., Kohrt, H. E. K., Zitvogel, L., et al. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.985940 · Cited by 59
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR -Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial)
Le, X., Patel, J. D., Shum, E., Baik, C. S., Sanborn, R. E., Shu, C. A., Kim, C., Fidler, M. J., Hall, R. D., Elamin, Y. Y., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00533 · Cited by 56
AACR Cancer Progress Report 2015
Baselga, J. M., Bhardwaj, N., Cantley, L. C., DeMatteo, R. P., DuBois, R. N., Foti, M., Gapstur, S. M., Hahn, W. C., Helman, L. J., Jensen, R. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1846 · Cited by 60
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial
Goss, G. D., Felip, E., Cobo, M., Lu, S., Syrigos, K., Lee, K. H., Göker, E., Georgoulias, V., Li, W., Guclu, S., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0775 · Cited by 55
Self-citation
PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
Tanvetyanon, T., Gray, J. E., & Antonia, S. J. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1280454 · Cited by 54
Antiangiogenic Therapies in Non-Small-Cell Lung Cancer
Alshangiti, A., Chandhoke, G., & Ellis, P. M. (2018) · Current Oncology · doi:10.3747/co.25.3747 · Cited by 54
RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancerPreprint
Sorokin, M., Poddubskaya, E. V., Baranova, M. P., Glusker, A., Kogoniya, L. M., Васильевна, М. Е., Allina, D. O., Suntsova, M., Tkachev, V., Garazha, A., et al. (2020) · Molecular Case Studies · doi:10.1101/mcs.a004945 · Cited by 55
SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015
García‐Campelo, R., Bernabé, R., Cobo, M., Corral, J., Coves, J., Dómine, M., Nadal, E., Rodríguez‐Abreu, D., Viñolas, N., & Massutí, B. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1455-z · Cited by 55
Ramucirumab: preclinical research and clinical development
Aprile, G., Fontanella, C., Rihawi, K., Grossi, F., & Rijavec, E. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s61132 · Cited by 53
Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy
Kazandjian, D. G., Khozin, S., Blumenthal, G. M., Zhang, L., Tang, S. W., Libeg, M., Kluetz, P. G., Sridhara, R., Keegan, P., & Pazdur, R. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.3934 · Cited by 53
Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer
Liang, H., & Wang, M. (2019) · Cancer Management and Research · doi:10.2147/cmar.s212238 · Cited by 54
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
Reck, M., Frost, N., Peters, S., Fox, B. A., Ferrara, R., Savai, R., & Barlési, F. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01061-7 · Cited by 62
Self-citation
Targeting the VEGF pathway in metastatic bladder cancer
Mazzola, C. R., & Chin, J. L. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1041588 · Cited by 51
Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR -mutant Non–small Cell Lung Cancer
Yu, H. A., Paz-Ares, L. G., Yang, J. C., Lee, K. H., Garrido, P., Park, K., Kim, J.-H., Lee, K. H., Mao, H., Wijayawardana, S. R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1690 · Cited by 50
Self-citation
Future options of anti-angiogenic cancer therapy
Cao, Y. (2016) · 癌症：英文版 · doi:10.1186/s40880-016-0084-4 · Cited by 51
Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?
Coelho, A., Gomes, M. P., Catarino, R., Rolfo, C. D., Lopes, A. M., Medeiros, R., & Araújo, A. (2016) · Oncotarget · doi:10.18632/oncotarget.7794 · Cited by 50
Anti-angiogenic Agents: A Review on Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors
Cheng, K., Liu, C., & Rao, G. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200514082425 · Cited by 52
Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies
Cao, H., Huang, T., Dai, M., Kong, X., Liu, H., Zheng, Z., Sun, G., Sun, G., Rong, D., Jin, Z., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.73949 · Cited by 51
Biological therapies in nonsmall cell lung cancer
Zugazagoitia, J., Molina‐Pinelo, S., López‐Ríos, F., & Paz-Ares, L. G. (2017) · European Respiratory Journal · doi:10.1183/13993003.01520-2016 · Cited by 49
Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer
Hardin, C., Shum, E., Ap, S., Perez-Soler, R., & Cheng, H. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1316374 · Cited by 49
Counter regulation of tumor angiogenesis by vascular endothelial growth factor and thrombospondin-1
Lawler, J. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.09.006 · Cited by 49
Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer
Bhalla, S., Fattah, F. J., Ahn, C. W., Williams, J. N., Macchiaroli, A., Padro, J., Pogue, M., Dowell, J. E., Putnam, W. C., McCracken, N. W., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107291 · Cited by 50
Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non–Small Cell Lung Cancer Patients
Kurzrock, R., & Stewart, D. J. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1968 · Cited by 49
Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer
Yamaguchi, O., Imai, H., Minemura, H., Suzuki, K., Wasamoto, S., Umeda, Y., Osaki, T., Kasahara, N., Uchino, J., Sugiyama, T., et al. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04055-7 · Cited by 47
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
Ben-Aharon, O., Magnezi, R., Leshno, M., & Goldstein, D. A. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0175 · Cited by 47
Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines
Passiglia, F., Pilotto, S., Facchinetti, F., Bertolaccini, L., Re, M. D., Ferrara, R., Franchina, T., Malapelle, U., Menis, J., Passaro, A., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102858 · Cited by 48
Treatment Considerations for Patients With Advanced Squamous Cell Carcinoma of the Lung
Santos, E. S., & Rodríguez, E. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.06.002 · Cited by 46
Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer
Keating, G. M. (2016) · Drugs · doi:10.1007/s40265-016-0589-9 · Cited by 45
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer
Reck, M., Paz-Ares, L. G., Bidoli, P., Cappuzzo, F., Dakhil, S. R., Moro‐Sibilot, D., Borghaei, H., Johnson, M. L., Jotte, R. M., Pennell, N. A., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.07.038 · Cited by 46
Self-citation
Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer
Tian, W., Cao, C., Shu, L., & Wu, F. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s276150 · Cited by 46
Current status of immunotherapy for non-small cell lung cancer
Yang, T., Xiong, Y., Zeng, Y., Wang, Y., Zeng, J., Liu, J., Xu, S., & Li, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.989461 · Cited by 45
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential
Wurz, G. T., Kao, C.-J., & DeGregorio, M. W. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015615514 · Cited by 49
Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies
Scarpace, S. L. (2015) · Drugs in Context · doi:10.7573/dic.212289 · Cited by 45
Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come
Toschi, L., Rossi, S., Finocchiaro, G., & Santoro, A. (2017) · ecancermedicalscience · doi:10.3332/ecancer.2017.787 · Cited by 48
Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995–2017
Takano, N., Ariyasu, R., Koyama, J., Sonoda, T., Saiki, M., Kawashima, Y., Oguri, T., Hisakane, K., Uchibori, K., Nishikawa, S., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.03.008 · Cited by 45
Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study
Zhang, K., Ma, X., Gao, H., Wang, H., Qin, H., Yang, S., & Liu, X. (2020) · Cancer Management and Research · doi:10.2147/cmar.s246000 · Cited by 45
The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies
García-Sampedro, A., Gaggia, G., Ney, A., Mahamed, I., & Acedo, P. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040566 · Cited by 47
Targeting KRAS G12C with Covalent Inhibitors
Ostrem, J. M. L., & Shokat, K. M. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-041621-012549 · Cited by 43
Overcoming KRAS-Mutant Lung Cancer
Luo, J., Ostrem, J. M. L., Pellini, B., Imbody, D., Stern, Y. E., Solanki, H. S., Haura, E. B., & Villaruz, L. C. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_360354 · Cited by 46
More to the RAS Story: KRAS G12C Inhibition, Resistance Mechanisms, and Moving Beyond KRAS G12C
Lietman, C. D., Johnson, M. L., McCormick, F., & Lindsay, C. R. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351333 · Cited by 44
Tumor microenvironment in lung cancer-derived brain metastasis
Liu, W., Powell, C. A., & Wang, Q. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002127 · Cited by 49
Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy
Pérol, M., Ciuleanu, T., Arrieta, O. G., Prabhash, K., Syrigos, K. N., Göksel, T., Park, K., Kowalyszyn, R. D., Pikiel, J., Lewanski, C. R., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.01.007 · Cited by 44
Self-citation
Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study
Kakimi, K., Matsushita, H., Masuzawa, K., Karasaki, T., Kobayashi, Y., Nagaoka, K., Hosoi, A., Ikemura, S., Kitano, K., Kawada, I., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001185 · Cited by 48
Treatment of advanced non-small-cell lung cancer
Prabhash, K., Vora, A. D., Limaye, S. A., Sahoo, T. P., Batra, U., Patil, S., Patil, V., Noronha, V., Bhosale, B., Raut, N. V., et al. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_61_21 · Cited by 46
Self-citation
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
Li, Z., Dang, X., Huang, D., Jin, S., Li, W., Shi, J., Wang, X., Zhang, Y., Song, Z., Zhang, J., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00110-3 · Cited by 49
Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor ( EGFR ) mutations and anaplastic lymphoma kinase ( ALK ) translocations – Still a daily challenge
Su, C., Zhou, F., Shen, J., Zhao, J., & O'Brien, M. E. R. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.002 · Cited by 44
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer
Bonomi, P., Gandara, D. R., Hirsch, F. R., Kerr, K. M., Obasaju, C. K., Paz-Ares, L. G., Bellomo, C., Bradley, J. D., Bunn, P. A., Culligan, M. J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy196 · Cited by 44
Self-citation
Update in Lung Cancer 2014
Spira, A. E., Halmos, B., & Powell, C. A. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201504-0756up · Cited by 44
Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia
Watanabe, N., Niho, S., Kirita, K., Umemura, S., Matsumoto, S., Yoh, K., Ohmatsu, H., & Goto, K. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2775-y · Cited by 42
Spotlight on Sotorasib (AMG 510) for KRASG12C Positive Non-Small Cell Lung Cancer
Zhang, S. S., & Nagasaka, M. (2021) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s334623 · Cited by 44
Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 – April 1, 2016, Tours, France
Désoubeaux, G., Reichert, J. M., Sleeman, M. A., Reckamp, K. L., Ryffel, B., Adamczewski, J. P., Sweeney, T. D., Rita Vanbever, A., Diot, P., Owen, C. A., et al. (2016) · mAbs · doi:10.1080/19420862.2016.1196521 · Cited by 43
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)
Proto, C., Ganzinelli, M., Manglaviti, S., Imbimbo, M., Galli, G., Marabese, M., Zollo, F., Alvisi, M. F., Perrino, M., Cordua, N., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.06.002 · Cited by 42
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
Shi, Y., Fang, J., Xing, L., Yao, Y., Zhang, J., Liu, L., Wang, Y., Hu, C., Xiong, J., Liu, Z., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03401-z · Cited by 42
U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy
Larkins, E. A., Scepura, B., Blumenthal, G. M., Bloomquist, E. W., Tang, S. W., Biable, M., Kluetz, P. G., Keegan, P., & Pazdur, R. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0221 · Cited by 42
Bevacizumab beyond disease progression after first‐line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer ( W est J apan O ncology G roup 5910L): An open‐label, randomized, phase 2 trial
Takeda, M., Yamanaka, T., Seto, T., Hayashi, H., Azuma, K., Okada, M., Sugawara, S., Daga, H., Hirashima, T., Yonesaka, K., et al. (2016) · Cancer · doi:10.1002/cncr.29893 · Cited by 44
Targeting the PD-1/PD-L1 axis in non–small cell lung cancer
Kumar, R., Collins, D. C., Dolly, S. O., McDonald, F., O'Brien, M. E. R., & Yap, T. A. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.12.002 · Cited by 45
Population pharmacokinetic meta‐analysis of ramucirumab in cancer patients
O’Brien, L. M., Westwood, P., Gao, L., & Heathman, M. A. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13403 · Cited by 42
Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer
Kubota, K., Yoshioka, H., Oshita, F., Hida, T., Yoh, K., Hayashi, H., Kato, T., Kaneda, H., Yamada, K., Tanaka, H., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.7297 · Cited by 42
Self-citation
Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program
Corral, J., Majem, M., Rodríguez‐Abreu, D., Carcereny, E., Cortes, A. A., Llorente, M. D. M., López-Picazo, J. M., García, Y. G., Dómine, M., & Criado, M. P. L. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02053-7 · Cited by 42
Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?
Popat, S., Grohé, C., Corral, J., Reck, M., Novello, S., Gottfried, M., Radonjic, D., & Kaiser, R. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.04.009 · Cited by 42
Self-citation
Therapeutic targeting of TGF ‐β in lung cancer
Aftabi, S., Behrooz, A. B., Cordani, M., Rahiman, N., Sadeghdoust, M., Aligolighasemabadi, F., Pistorius, S., Alavizadeh, S. H., Taefehshokr, N., & Ghavami, S. (2024) · FEBS Journal · doi:10.1111/febs.17234 · Cited by 42
Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer
Digumarti, R., Bapsy, P. P., Suresh, A. V., Bhattacharyya, G. S., Dasappa, L., Shan, J. S., & Gerber, D. E. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.08.010 · Cited by 41
Sox7 promotes high-grade glioma by increasing VEGFR2-mediated vascular abnormality
Kim, I., Kim, K., Lee, E., Oh, D. S., Park, C. S., Park, S., Yang, J. M., Kim, J.-H., Kim, H.-S., Shima, D. T., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20170123 · Cited by 40
Self-citation
Therapeutic antibodies: A new era in the treatment of respiratory diseases?
Sécher, T., Guilleminault, L., Reckamp, K. L., Amanam, I. U., Plantier, L., & Heuzé‐Vourc'h, N. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.003 · Cited by 42
FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations
Mehta, G. U., Vellanki, P. J., Ren, Y., Amatya, A. K., Mishra-Kalyani, P. S., Pan, L., Zirkelbach, J. F., Pan, Y., Liu, J., Aungst, S. L., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae151 · Cited by 40
National trends in prescription drug expenditures and projections for 2015
Schumock, G. T., Li, E. C., Suda, K. J., Wiest, M. D., Stubbings, J., Matusiak, L. M., Hunkler, R. J., & Vermeulen, L. C. (2015) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp140849 · Cited by 38
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer
Park, W., Kasi, A., Spira, A. I., Rodríguez, L. P.-A., Herzberg, B. O., Pelster, M. S., Tolcher, A. W., Kuboki, Y., Kitano, S., Shoji, H., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2600752 · Cited by 46
Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials
Xiao, B., Wang, W., & Zhang, D. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s166151 · Cited by 40
A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer
Harding, J. J., Zhu, A. X., Bauer, T. M., Choueiri, T. K., Drilon, A. E. D. C., Voss, M. H., Fuchs, C. S., Abou‐Alfa, G. K., Wijayawardana, S. R., Wang, X. A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4010 · Cited by 39
Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing
Leclerc, M., Mezquita, L., Nerville, G. G. D., Tihy, I., Malenica, I., Chouaïb, S., & Mami‐Chouaib, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01505 · Cited by 40
Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer
Khan, U., & Shah, M. A. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1656715 · Cited by 39
Different Forms of Tumor Vascularization and Their Clinical Implications Focusing on Vessel Co-option in Colorectal Cancer Liver Metastases
Haas, G., Fan, S., Ghadimi, M. B., Oliveira, T. D., & Conradi, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.612774 · Cited by 39
Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer
Choi, S. H., Yoo, S. S., Lee, S. Y., & Park, J. Y. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01382-6 · Cited by 40
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy
He, K., Berz, D., Gadgeel, S. M., Iams, W. T., Bruno, D. S., Blakely, C. M., Spira, A. I., Patel, M. R., Waterhouse, D. M., Richards, D., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.02.016 · Cited by 40
Self-citation
Immunotherapy for non-small cell lung cancer: current concepts and clinical trials
Mayor, M., Yang, N., Sterman, D. H., Jones, D. R., & Adusumilli, P. S. (2015) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezv371 · Cited by 38
The Story of Angiogenesis Inhibitors in Non–small-cell Lung Cancer: The Past, Present, and Future
Shukla, N. A., Yan, M., & Hanna, N. H. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.02.024 · Cited by 38
HOX Genes Family and Cancer: A Novel Role for Homeobox B9 in the Resistance to Anti-Angiogenic Therapies
Contarelli, S., Fedele, V., & Melisi, D. (2020) · Cancers · doi:10.3390/cancers12113299 · Cited by 37
Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064)
O'Brien, M. E. R., Gaafar, R. M., Hasan, B., Menis, J., Čufer, T., Popat, S., Woll, P. J., Surmont, V. F. M., Georgoulias, V., Montes, A., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.04.026 · Cited by 37
Evolution of ramucirumab in the treatment of cancer – A review of literature
Vennepureddy, A., Singh, P., Rastogi, R., Atallah, J. P., & Terjanian, T. (2016) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155216655474 · Cited by 36
Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer
Lazzari, C., Bulotta, A., Ducceschi, M., Viganò, M. G., Brioschi, E., Corti, F., Gianni, L., & Gregorc, V. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00004 · Cited by 37
The emerging treatment landscape of advanced non-small cell lung cancer
Economopoulou, P., & Mountzios, G. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2017.11.07 · Cited by 36
Salvage treatment with anlotinib for advanced non‐small cell lung cancer
Wu, D., Nie, J., Dai, L., Hu, W., Zhang, J., Chen, X., Ma, X., Tian, G., Han, J., Han, S., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13120 · Cited by 36
Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment
Tozuka, T., Kitazono, S., Sakamoto, H., Yoshida, H., Amino, Y., Uematsu, S., Yoshizawa, T., Hasegawa, T., Ariyasu, R., Uchibori, K., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.04.021 · Cited by 37
Therapeutic Antibodies by Phage Display
Shim, H. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160923113714 · Cited by 36
The effect of lengths of branched-chain fatty alcohols on the efficacy and safety of docetaxel-prodrug nanoassemblies
Wang, S., Liu, T., Huang, Y., Du, C., Wang, D., Wang, X., Lv, Q., He, Z., Zhai, Y., Sun, B., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.09.017 · Cited by 35
Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study
Yardley, D. A., Reeves, J. A., Dees, E. C., Osborne, C. R. C., Paul, D., Ademuyiwa, F. O., Soliman, H. H., Guthrie, T. H., Andersen, J., Krekow, L., et al. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.07.005 · Cited by 35
Ramucirumab in the treatment of non-small cell lung cancer
Arrieta, O. G., Zatarain-Barrón, Z. L., Cardona, A. F., Carmona, A., & López-Mejía, M. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1313226 · Cited by 35
Self-citation
Sequential Therapy with Ramucirumab and/or Checkpoint Inhibitors for Non-Small-Cell Lung Cancer in Routine Practice
Molife, C., Hess, L. M., Cui, Z. L., Li, X. I., Beyrer, J. K., Mahoui, M., & Oton, A. B. (2019) · Future Oncology · doi:10.2217/fon-2018-0876 · Cited by 35

A Randomized, Double-Blind, Phase III Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non–Small-Cell Lung Cancer After Disease Progression After 1 Previous Platinum-Based Therapy (REVEL): Treatment Rationale and Study Design
Garon, E. B., Cao, D., Alexandris, E., John, W. J., Yurasov, S., & Pérol, M. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.06.007 · Cited by 40
Self-citation
REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy.
Pérol, M., Ciuleanu, T., Arrieta, O. G., Prabhash, K., Syrigos, K. N., Göksel, T., Park, K., Kowalyszyn, R. D., Pikiel, J., Czyżewicz, G., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.lba8006 · Cited by 17
Self-citation
A multicenter, double-blind, randomized phase III trial of ramucirumab plus docetaxel versus placebo plus docetaxel for treatment of Stage IV non-small cell lung cancer after disease progression on or after platinum-based therapy (REVEL): An Indian patient subgroup analysis
Prabhash, K., Doval, D. C., Rangarajan, B., Somani, N., Pruthi, A., Dyachkova, Y., & Puri, T. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_159_21 · Cited by 3
Self-citation
A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy
Yoh, K., Hosomi, Y., Kasahara, K., Yamada, K., Takahashi, T., Yamamoto, N., Nishio, M., Ohe, Y., Koue, T., Nakamura, T., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.07.019 · Cited by 110
Update of REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line (2L) treatment of stage IV non-small cell lung cancer (NSCLC) including subgroup analysis of histology
Bidoli, P., Cappuzzo, F., Favaretto, A. G., Alabiso, O., Tiseo, M., Chella, A., Gebbia, V., Pizzuti, L., Paz-Ares, L. G., Pérol, M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv343.04 · Cited by 2
Self-citation

See all

Authors: Garon, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., Czyzewicz, G., Orlov, S. V., Lewanski, C. R., Thomas, M., Bidoli, P., Dakhil, S., Gans, S., Kim, J.-H., Grigorescu, A., Karaseva, N., Reck, M., Cappuzzo, F., Alexandris, E., Sashegyi, A., Yurasov, S., & Pérol, M.
Affiliations: University of California, Los Angeles (US)
Iuliu Hațieganu University of Medicine and Pharmacy (RO)
Instituto Nacional de Cancerología (MX)
Tata Memorial Hospital (IN)
Sotiria General Hospital (GR)
Samsung Medical Center (KR)
Russian Cancer Research Center NN Blokhin (RU)
Charing Cross Hospital (GB)
University Hospital Heidelberg (DE)
Azienda Ospedaliera San Gerardo (IT)
Cancer Center of Kansas (US)
Gemeinschaftskrankenhaus Herdecke (DE)
Yonsei University Health System (KR)
Institutul Oncologic Bucuresti (RO)
City Clinical Oncology Center (RU)
German Center for Lung Research (DE)
Ospedale di Livorno (IT)
Eli Lilly (United States) (US)
Corresponding author: Garon, Edward B
ORCID: Garon, Edward B
Ciuleanu, Tudor-Eliade
Arrieta, Oscar
Prabhash, Kumar
Park, Keunchil
Gorbunova, Vera
Pikiel, Joanna
Thomas, Michael
Dakhil, Shaker
Kim, Joo-Hang
Grigorescu, Alexandru
Reck, Martin
Cappuzzo, Federico
Sashegyi, Andreas
Yurasov, Sergey
Venue: The Lancet
Publisher: Elsevier BV
Published: 2014-08
Volume: 384
Issue: 9944
Pages: 665-673
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(14)60845-x
OpenAlex: W2140980839
Cited by: 1,309
References: 35
Citations by year: 2026: 57 · 2025: 71 · 2024: 116 · 2023: 102 · 2022: 110 · 2021: 97 · 2020: 108 · 2019: 102 · 2018: 106 · 2017: 148 · 2016: 155 · 2015: 115 · 2014: 19
FWCI: 116.89
Type: journal article
Language: en
Open access: green
www.sciencedirect.com
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
BOA (University of Milano-Bicocca) (submittedVersion)
YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: ramucirumab, docetaxel, non-small cell lung cancer, second-line therapy, VEGFR-2 inhibition, anti-angiogenic therapy, overall survival, progression-free survival, adverse events, drug safety, maintenance therapy, lung squamous cell carcinoma, non-squamous cell lung cancer
MeSH terms: Docetaxel, Ramucirumab, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Placebos, Platinum, Quality of Life, Survival Rate, Disease Progression, Taxoids, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks